Priyanka Chablani presented a survey-based study at ASCO GU 2025, analyzing treatment sequencing after first-line enfortumab vedotin + pembrolizumab for locally advanced or metastatic urothelial ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...

Interdisciplinary GU Cancer Forum 2025 Combination Therapies in prostate cancer, active surveillance, GG1 prostate cancer, radical prostatectomy.

SNMMI 2025 novel PSMA-targeting drug 177Lu-P17-088, metastatic castration-resistant prostate cancer (mCRPC), VISION and PSMAfore trials, PCWG3 guidelines.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Peter Clark presented results from the SunRISe-1 study at SESAUA 2025, evaluating TAR-200, an intravesical sustained-release gemcitabine system, in BCG-unresponsive high-risk non-muscle invasive ...

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

Were you unable to attend APCCC 2024? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.

AUA 2024, Non–muscle-Invasive Bladder Cancer (NMIBC), TAR-210, erdafitinib, MoonRISe-1 study, FGFR Alterations, tyrosine kinase inhibitor, gemcitabine.

Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test. Dr. Showalter explains how ArteraAI analyzes H&E-stained biopsy slides using computer ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer oral abstract session and a presentation by Dr. Theodore DeWeese discussing a phase 3, randomized, placebo-controlled clinical ...